On Thursday, Novogen Limited (ADR) (NASDAQ:NVGN)’s shares declined -7.29% to $5.09.
Novogen Limited (ADR) (NVGN) confirms that a lipid formulation of TRXE-009 dosed intravenously to animals was able to deliver therapeutic concentrations of TRXE-009 to brain tissue. This confirms that the drug is able to cross the blood brain barrier.
The blood-brain barrier is a defence mechanism intended to protect the brain from the unwanted toxic effects of drugs and food chemicals. It serves to prevent some 98% of all drugs used in humans from reaching the brain. This, plus the inherent resistance of primary brain cancers to chemotherapies, is the reason behind the poor survival prospects of adults and children with brain cancer.
Novogen Limited is engaged in the pharmaceutical research and development business in Australia. The company has primarily two drug technology platforms, which comprise super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). Its SBPs technology platform offers drug candidates, which comprise Cantrixil, an intra-peritoneal product intended for the treatment of abdominal cancers, such as ovarian and pancreatic cancer; Trilexium that is intended for the treatment of neural cancers, counting glioblastoma and neuroblastoma; and Trx-7 for the treatment of prostate cancer.
Sanofi SA (ADR) (NYSE:SNY)’s shares dropped -0.68% to $50.75.
Genzyme, a Sanofi SA (ADR) (SNY) company, declared that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olipudase alfa. This enzyme replacement therapy is being investigated for the treatment of patients with nonneurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease type B, as opposed to type A which is characterized by neurological involvement. ASMD is a serious and life-threatening disorder caused by insufficient activity of the enzyme acid sphingomyelinase (ASM), which results in toxic accumulation of sphingomyelin. There are presently no approved treatment options for patients with Niemann-Pick disease type B.
Breakthrough Therapy designation is intended to expedite the development and review of investigational new drugs that target serious or life-threatening conditions. The criteria for granting Breakthrough Therapy designation are preliminary clinical evidence of substantial improvement on a clinically noteworthyendpoint over accessible therapies. The Breakthrough Therapy designation is distinct from the FDA’s other mechanisms to expedite drug development and review, and will allow for a close partnership between Genzyme and the FDA on the olipudase alfa development program.
Olipudase alfa is being developed by Genzyme to potentially address the fundamental defect underlying the disease. Supplementing the defective or deficient native enzyme with olipudase alfa allows for the breakdown of sphingomyelin, whose accumulation is responsible for the clinical manifestation of ASMD.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine.
At the end of Thursday’s trade, Sempra Energy (NYSE:SRE)‘s shares dipped -0.44% to $104.30.
SDG&E is a partner of Sempra Energy (SRE). San Diego Gas & Electric (SDG&E) and groups representing environmental, environmental justice, electric vehicle service providers, automakers and labor signed a settlement agreement in support of SDG&E’s innovative Electric Vehicle Grid-Integration pilot project. The pilot calls for SDG&E to install electric vehicle (EV) charging infrastructure at up to 550 sites throughout the utility’s service territory and offer special rates to encourage charging at optimal times for the grid. These diverse organizations have come together to make this pilot program a key step in meeting Governor Jerry Brown’s aim of having 1.5 million zero emission vehicles on California roads by 2025.
The agreement calls for SDG&E to install charging infrastructure at up to 550 business and multi-family locations throughout its service territory, with 10 chargers at each location for a total of 5,500 separate chargers. Building owners and managers would have a choice of grid-integrated rate options and equipment, promoting competition and market growth in this nascent industry. SDG&E would install at least 10 percent of the chargers in economically disadvantaged communities to expand access to clean EVs in these underserved areas. The pilot will feature special rates that encourage EV customers to lower their fueling costs by charging their cars when electricity supply, counting renewable energy is plentiful and energy prices are low. With rates encouraging off-peak charging, vehicles would be efficiently integrated onto the grid, assisting to avoid on-peak charging that drives the need to build more power plants and other electrical infrastructure.
Sempra Energy operates as an energy services holding company worldwide. The companys San Diego Gas & Electric Company segment transmits and distributes electricity and/or natural gas. As of February 23, 2015, this segment offered energy service about to 3.4 million consumers through 1.4 million electric meters and 878,000 natural gas meters in San Diego and southern Orange counties.
Memorial Resource Development Corp (NASDAQ:MRD), ended its Thursday’s trading session with -0.22% loss, and closed at $19.18.
Memorial Resource Development Corp (MRD) declared that John A. Weinzierl, Chief Executive Officer, and Andrew J. Cozby, Senior Vice President and Chief Financial Officer, are planned to take part at the following investor conferences:
- Raymond James Boston Spring Investors Conference in Boston, Massachusetts on Tuesday, June 9, 2015; and
- Tudor, Pickering, Holt & Co. Hotter ‘N Hell Conference in Houston, Texas on Wednesday, June 17, 2015 through Thursday, June 18, 2015.
Memorial Resource Development Corp., an independent natural gas and oil company, focuses on the acquisition, exploitation, and development of natural gas, natural gas liquids, and oil properties primarily in North Louisiana. As of December 31, 2014, the company held leasehold interest in 210,854 net acres; and had estimated proved reserves of about 1,632 billion cubic feet of natural gas equivalent. The company was founded in 2011 and is based in Houston, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
